Doxecitine
Doxecitine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
129 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | 1 | 1 | 2 | — | 8 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 1 | 1 | 1 | — | 6 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | 1 | — | 3 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | — | — | 1 | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 35 | 36 | 3 | — | 2 | 65 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 30 | 31 | 2 | — | 2 | 55 |
| Myeloid leukemia | D007951 | — | C92 | 28 | 32 | 2 | — | 2 | 55 |
| Myelodysplastic syndromes | D009190 | — | D46 | 21 | 28 | 4 | — | 1 | 44 |
| Preleukemia | D011289 | — | — | 19 | 23 | 3 | — | 1 | 37 |
| Syndrome | D013577 | — | — | 20 | 20 | 2 | — | 1 | 35 |
| Recurrence | D012008 | — | — | 11 | 6 | 1 | — | — | 15 |
| Carcinoma | D002277 | — | C80.0 | 5 | 4 | 1 | — | — | 7 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 2 | 5 | 1 | — | — | 6 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 5 | 2 | — | — | 5 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 15 | 7 | — | — | 2 | 22 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 6 | 8 | — | — | 1 | 13 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 6 | 8 | — | — | 1 | 13 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 7 | 6 | — | — | 1 | 12 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 5 | 4 | — | — | — | 7 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 4 | — | — | — | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 5 | 1 | — | — | — | 5 |
| Fallopian tube neoplasms | D005185 | — | — | 3 | 2 | — | — | — | 4 |
| Hematologic neoplasms | D019337 | — | — | 3 | 1 | — | — | — | 4 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 3 | — | — | — | 4 |
Show 47 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 3 | — | — | — | — | 3 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 2 | — | — | — | — | 2 |
| Refractory anemia | D000753 | — | D46.4 | 2 | — | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | 2 | — | — | — | — | 2 |
| Plasmacytoma | D010954 | — | C90.3 | 2 | — | — | — | — | 2 |
| Bone marrow diseases | D001855 | — | — | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Doxecitine |
| INN | doxecitine |
| Description | Deoxycytidine is a deoxyribonucleoside, a component of deoxyribonucleic acid. It is similar to the ribonucleoside cytidine, but with one hydroxyl group removed from the C2' position.
|
| Classification | Small molecule |
| Drug class | H2-receptor antagonists (cimetidine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 951-77-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL66115 |
| ChEBI ID | 15698 |
| PubChem CID | 637 |
| DrugBank | DB02594 |
| UNII ID | 0W860991D6 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30,247 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use